Breast-conserving therapy in older patients with breast cancer over three decades: progress or stagnation.

Autor: Jobsen JJ; Department of Epidemiology, Medisch Spectrum Twente, Enschede, The Netherlands; Department of Radiation Oncology, Medisch Spectrum Twente, Enschede, The Netherlands; Breast Clinic Oost-Nederland, Ziekenhuis Groep Twente, Hengelo, The Netherlands. Electronic address: jjjobsen@hetnet.nl., Middelburg JG; Department of Radiotherapy, Erasmus Medical Center Rotterdam, The Netherlands., van der Palen J; Department of Epidemiology, Medisch Spectrum Twente, Enschede, The Netherlands; Department of Research Methodology, Measurement, and Data Analysis, Faculty of Behavioral Science, University of Twente, The Netherlands., Riemersma S; Laboratory for Pathology Oost Nederland, Hengelo, The Netherlands., Siemerink E; Department of Internal Medicine, Ziekenhuis Groep Twente, Hengelo, The Netherlands., Struikmans H; Department of Radiation Oncology, Leiden University Medical Centre, Leiden, The Netherlands., Siesling S; Department of Research, Netherlands Comprehensive Cancer Organization, Utrecht, The Netherlands; Department of Health Technology and Services Research, MIRA Institute of Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands.
Jazyk: angličtina
Zdroj: Journal of geriatric oncology [J Geriatr Oncol] 2019 Mar; Vol. 10 (2), pp. 330-336. Date of Electronic Publication: 2018 Aug 18.
DOI: 10.1016/j.jgo.2018.08.007
Abstrakt: Background: The aim of this study was to analyze the distant metastases-free survival (DMFS), and disease-specific survival (DSS) after breast-conserving therapy (BCT) in older patients with breast cancer in a large, population-based, single-center cohort study with long-term follow-up.
Material and Methods: Analyses were based on 1,425 women aged 65 years and older with breast cancer treated with BCT. Patients were divided in three age categories: 65 - 70 years, 71 - 75 years, and >75 years. The study period extended over 30 years, divided in three decades. Multivariate survival analysis was carried out using Cox regression analysis.
Results: The two youngest age categories showed significant improvements over time in 12-year DMFS and DSS. For women aged 65 - 70 years, this improvement was noted in stage I and stage II disease, while for women aged 71 - 75 years this was mainly in stage II tumors. Women >75 years of age did not show any improvement over time, regardless of stage.
Conclusion: Among older Dutch women with breast cancer, outcomes with regard to DMFS and DSS after BCT differ between various age categories, showing the least gain in the very old.
(Copyright © 2018 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: